Preference Tiotropium Respimat Study in COPD

Boehringer Ingelheim150 enrolled

Overview

In COPD the patient's ability to use inhalers correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for COPD. This is a cross-sectional study where satisfaction, preference and handling of two different devices such as Respimat and Breezhaler will be evaluated by using the validated PASAPQ in COPD patients

Purpose: Study Design:

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Group1:Spiriva® Respimat®DEVICE

COPD patients using Respimat®

Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®DEVICE

COPD patients using Breezhaler®®

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: 1. All patients must sign an informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in the study and conducting any study procedures. 2. Adult male or female patients with chronic obstructive pulmonary disease (COPD) for less than a year who follow usual clinical practice of the participant sites and who are on treatment with Spiriva® Respimat®, Hirobriz® Breezhaler® / Onbrez® Breezhaler® / Oslif® Breezhaler® for at least of 3 months but not more than maximum of 6 months before the informed consent date. Exclusion criteria: 1. Previously included in this study or currently participating in another interventional study. 2. Visual, cognitive, or motor impairment that as judged by the investigator does not allow the patient to independently read and complete the questionnaire. 3. Patients who are treated simultaneously with both respiratory medications (Spiriva® Respimat® and Hirobriz® Breezhaler® / Onbrez® Breezhaler® / Oslif® Breezhaler®).

Locations (15)

Boehringer Ingelheim Investigational Site 13

A Coruña, Spain

Boehringer Ingelheim Investigational Site 5

Barcelona, Spain

Boehringer Ingelheim Investigational Site 6

Outcomes

Primary Outcomes

Total Mean Score of the Validated Patient Satisfaction and Preference Questionnaire (PASAPQ)

Patient satisfaction with regard to the total score of the handling of the inhaled devices performed by means of a PASAPQ. All questions were answered on a 7-point scale ranging from 1= very dissatisfied to 7 = very satisfied).To calculate the total score, the sum of the 13 items of the two domains (performance and convenience) was transformed to a 0- (least) to 100- (most) point scale which is scaled positively:higher scores represent higher levels of satisfaction.

Time frame: day 1

Secondary Outcomes

Total Performance PASAPQ Score.

All questions were answered on a 7-point scale ranging from 1= very dissatisfied to 7 = very satisfied).To calculate the domain scores, the sum of the items of the performance domain was transformed to a 0- (least) to 100- (most) point scale which is scaled positively:higher scores represent higher levels of satisfaction.

Time frame: day 1

Total Convenience PASAPQ Score

All questions were answered on a 7-point scale ranging from 1= very dissatisfied to 7 = very satisfied).To calculate the domain scores, the sum of the items of the convenience domain was transformed to a 0- (least) to 100- (most) point scale which is scaled positively:higher scores represent higher levels of satisfaction.

Time frame: day 1

Overall Satisfaction Question

The overall satisfaction ranges from 1=very dissatisfied to 7=very satisfied.

Time frame: day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.